nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

06.05.2022 | Letter to the Editor

[¹⁷⁷Lu]Lu-DOTATATE peptide receptor radionuclide therapy–associated myeloid neoplasms: insights from the WHO pharmacovigilance database

verfasst von: Jonathan Vigne, Basile Chrétien, Anne-Laure Bignon, Karine Bouhier-Leporrier, Charles Dolladille

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 10/2022

Einloggen, um Zugang zu erhalten

Excerpt

Dear Sir, …

Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, et al. 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22:1752–63. https://doi.org/10.1016/S1470-2045(21)00572-6. CrossRefPubMed

Goncalves I, Burbury K, Michael M, Iravani A, Ravi Kumar AS, Akhurst T, et al. Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series. Eur J Nucl Med Mol Imaging. 2019;46:1902–10. https://doi.org/10.1007/s00259-019-04389-2. CrossRefPubMed

Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–35. https://doi.org/10.1056/NEJMoa1607427. CrossRefPubMedPubMedCentral

van der Zwan WA, Brabander T, Kam BLR, Teunissen JJM, Feelders RA, Hofland J, et al. Salvage peptide receptor radionuclide therapy with [177Lu-DOTA, Tyr3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2019;46:704–17. https://doi.org/10.1007/s00259-018-4158-1. CrossRefPubMed

Titel: [177Lu]Lu-DOTATATE peptide receptor radionuclide therapy–associated myeloid neoplasms: insights from the WHO pharmacovigilance database
verfasst von: Jonathan Vigne
Basile Chrétien
Anne-Laure Bignon
Karine Bouhier-Leporrier
Charles Dolladille
Publikationsdatum: 06.05.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 10/2022
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-022-05833-6

Hauptrubriken

Service

Fachgebiete

Themen

Sammlungen

Springer Medizin

[¹⁷⁷Lu]Lu-DOTATATE peptide receptor radionuclide therapy–associated myeloid neoplasms: insights from the WHO pharmacovigilance database

Excerpt

Hauptrubriken

Service

Fachgebiete

Themen

Sammlungen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2022

Cervical lymph node staging in head and neck tumors: bridging the gap between humans and companion animals

First-time imaging of [89Zr]trastuzumab in breast cancer using a long axial field-of-view PET/CT scanner

Intraoperative MET-receptor targeted fluorescent imaging and spectroscopy for lymph node detection in papillary thyroid cancer: novel diagnostic tools for more selective central lymph node compartment dissection

FDG-PET/CT in indeterminate thyroid nodules: cost-utility analysis alongside a randomised controlled trial

To give or not to give? A critical appraisal of a clinical trial on radioiodine treatment

Hematologic toxicity profile and efficacy of [225Ac]Ac-PSMA-617 α-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer